Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
NCT07499583Phase 2Not yet recruiting
- Sponsor
- Indiana University
- Start
- Feb 2027
- Primary completion
- Feb 2031
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) and substance use disorder (SUD) (3 arms), sponsored by Indiana University. Primary endpoints: Adverse Events, Positive urines and 4 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)substance use disorder (SUD)
Beyond the preview
Go deeper on NCT07499583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499583.